Allo-HSCT
Sponsors
Yoshihiro Inamoto, Genetix Biotherapeutics Inc., National Research Center for Hematology, Russia, Shanghai Jiao Tong University School of Medicine, Peking University People's Hospital
Conditions
AMLAcute Myeloid LeukemiaAdrenoleukodystrophy (ALD)Bone Marrow Failure SyndromeCerebral Adrenoleukodystrophy (CALD)Hypoplastic Acute Myeloid LeukemiaModerate to severe steroid-refractory or steroid-dependent chronic GVHD.
cGVHDSchimke Immuno-osseous Dysplasia
Early Phase 1
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD
RecruitingNCT06769191
Start: 2025-01-30End: 2028-01-30Target: 20Updated: 2025-01-20
CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases
RecruitingNCT06787560
Start: 2025-01-31End: 2028-01-31Target: 20Updated: 2025-01-22
Phase 2
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Active, not recruitingNCT06497062
Start: 2024-10-30End: 2028-06-30Target: 47Updated: 2026-04-30
Belumosudil as Second-line Therapy for Chronic GVHD
Active, not recruitingJPRN-jRCTs041260046
Start: 2026-06-02Target: 41Updated: 2026-06-29
Unknown Phase
Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
TerminatedNCT02204904
Start: 2015-04-30End: 2019-12-06Updated: 2020-05-21
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission
RecruitingNCT05339204
Start: 2021-02-01End: 2026-02-01Target: 75Updated: 2022-04-21
Allo-HSCT vs ASCT in Adult T-LBL
Not yet recruitingNCT06741813
Start: 2025-01-01End: 2029-12-31Target: 230Updated: 2024-12-19
VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML
Not yet recruitingNCT07635485
Start: 2026-06-01End: 2029-08-31Target: 50Updated: 2026-06-09